Historical resistance profile helps to predict salvage failure

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 285-291

  Zaccarelli, Mauro ^a   Lorenzini, Patrizia ^a   Ceccherini Silberstein, Francesca ^a,b   Tozzi, Valerio ^a   Forbici, Federica ^a   Gori, Caterina ^a   Trotta, Maria P ^a   Boumis, Evangelo ^a   Narciso, Pasquale ^a   Perno, Carlo F ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS MUTATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MULTIDRUG RESISTANCE; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT FAILURE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HIV; HIV INFECTIONS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 67149083325     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Harrigan PR, Cote HC. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin Infect Dis 2000; 30 Suppl 2:S117-S122.
2. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
3. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
4. Panidou ET, Trikalinos TA, Ioannidis JP. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 2004; 18:2153-2161.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. 3 November 2008. (Updated 3 November 2008. Accessed 15 December 2008.) Available from http://www.aidsinfo.nih.gov
6. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006; 11:553-560.
7. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008; 16:62-68.
8. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
9. Zaccarelli M, Forbici F, Lorenzini P, et al. Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database. AIDS 2007; 21:1824-1826.
10. Costagliola D, Potard V, Duvivier C, et al. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. Antivir Ther 2005; 10:563-573.
11. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
12. Cozzi-Lepri A, Phillips A, Mocroft A, Kirk O, Ruiz L, Lundgren JD. Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. 10th European AIDS Conference. 17-20 November 2005, Dublin, Ireland. Abstract PS 3/4.
13. Deeks SG for the North America AIDS Cohort Collaboration in Research and Design (NA-ACCORD) of the IeDEA. The prevalence of multidrug resistance among treated patients in North America and its impact on mortality. Antivir Ther 2008; 13 Suppl 3:A153.
14. Lohse N, Jørgensen L, Obel N, Gerstoft J and the Danish HIV Cohort Study. Resistance mutations predict mortality in HIV patients with triple-class antiretroviral drug failure. 14th Conference on Retrovirus and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 659.
15. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.
16. Yerly S, Fagard C, Günthard HF, Hirschel B, Perrin L, Swiss HIV Cohort Study. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-415.
17. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-section.
18. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
19. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partly suppressive treatment regimen. Clin Infect Dis 2006; 43:1329-1336.
20. Tozzi V, Bellagamba R, Castiglione F, et al. Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple failures receiving resistance testing-guided HAART. AIDS Res Hum Retroviruses 2008; 24:787-796.
21. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-1647.
22. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.
23. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
24. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
25. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
26. Nelson M, Arastéh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-412.
27. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 15th Conference on Retrovirus and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 104aLB.
28. Cooper D, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. 15th Conference on Retrovirus and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 788.
29. Steigbigel R, Kumar P, Eron J, et al. 48-Week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing ART with triple-class resistant HIV. 15th Conference on Retrovirus and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 789.
30. Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis 2003; 37:1517-1526.
31. + cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med 2003; 139:810-816.